MedTrace Logo

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

NCT02867345 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-03-06

No results posted yet for this study

Summary

This study will evaluate the safety of PD-1 knockout engineered T cells in treating castration resistant prostate cancer (CRPC). Blood samples will also be collected for research purposes.

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

BIOLOGICAL

PD-1 Knockout T Cells

PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.

DRUG

Cyclophosphamide

Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).

DRUG

IL-2

Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).

Sponsors & Collaborators

  • Peking University

    lead OTHER

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02867345 on ClinicalTrials.gov